Tandem Diabetes Care Automated Insulin Delivery Systems Receive CE Mark for Type 2 Diabetes and Type 1 Diabetes During Pregnancy
Tandem Diabetes Care received CE Mark approval in Europe for its t:slim X2 and Tandem Mobi systems for use in Type 2 Diabetes and Type 1 Diabetes during pregnancy. The Type 1 pregnancy indication is supported by the CIRCUIT trial published in JAMA, which showed 12.6% more time in range (approx. 3 hours/day) compared to standard therapy.
Key figures
- Drug Name
- Control-IQ+ AID technology
- Tir hours added
- 3 hours
- A1c reduction t2
- 0.9%
- Trial participants t2
- 300+
- Tir improvement t1 pregnancy
- 12.6%
- A1c reduction t2 high baseline
- 2.3%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.